Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies. Based in Cambridge, Massachusetts, the firm partners with life science entrepreneurs to translate scientific breakthroughs into medicines.
31% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $58.0M (across 261 rounds with reported amounts).
Portfolio
199
Fund Size
$400M
Top Stage
Series A
Last 12 Mo
8
Team
Akshay Vaishnaw, MD, PhD
Venture Partner
Bob Copeland, PhD
Venture Partner
Bruce Booth, DPhil
Partner
Charlie Albright, PhD
Venture Partner
David Grayzel, MD
Partner
Jason Rhodes
Partner
Jean-François Formela, MD
Partner
Jeff Albers, JD, MBA
Venture Partner
Linda C. Bain
Venture Partner
Phillip Samayoa, PhD
Venture Partner; Chief Operating Officer, Ethyreal Bio
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Aiolos | Series A | $245M | Sep 2026 |
| VVima | Series A | $100M | Mar 2026 |
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| KKinaset | Series B | $103M | Jan 2026 |
 Caldera Therapeutics | Series A | $75M | Jan 2026 |
| VVima Therapeutics, Inc. | Unknown | $40M | Jan 2026 |
 Diagonal Therapeutics | Series B | $125M | Jan 2026 |
 Triana Biomedicines | Series B | $120M | Dec 2025 |
 Lifordi Immunotherapeutics | Unknown | — | Nov 2025 |
 AAVantgarde Bio | Series B | — | Nov 2025 |
| KKailera | Series B | $600M | Oct 2025 |
| VVima Therapeutics, Inc. | Series A | $60M | May 2025 |
 Exowatt | Series A | $50M | Apr 2025 |
 Verdiva Bio | Series A | $410M | Jan 2025 |
| Exowatt | Series A | $50M | Jan 2025 |
| VVima Therapeutics, Inc. | Series A | $60M | Jan 2025 |
| VVima | Series A | $60M | Jan 2025 |
 Trace Neuroscience | Series A | $101M | Nov 2024 |
 Triveni Bio | Series B | $115M | Oct 2024 |
| TTriveni | Series B | $115M | Oct 2024 |
 Kailera Therapeutics | Series A | — | Oct 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
 Secret Escapes | Series E | $60M | May 2024 |
| Diagonal Therapeutics | Series A | $128M | Apr 2024 |
 Obsidian Therapeutics | Series C | $160.5M | Apr 2024 |
Top Co-Investors
Last updated: 20 October 2026